PURPOSE: To analyze the role of negative versus positive immunoexpression of E-cadherin in recurrence rate of low-grade bladder tumors. MATERIALS AND METHODS: A total of 180 patients with unifocal, superficial, low-grade, papillary transitional cell carcinoma of the bladder were included in this study. The E-cadherin expression was evaluated using E-cadherin antibody. The patients were followed up for 36 months. Thereafter, recurrence rate of the tumor was compared between E-cadherin positive and negative groups. RESULTS: Of 180 low-grade carcinomas, E-cadherin immunoexpression was negative in 101 (56%) and positive in 79 (44%) patients. The recurrence rate in negative and positive groups was 65.6% and 37.9%, respectively. Negative in comparison with positive E-cadherin expression was associated with more disease recurrence (P = .045). CONCLUSION: There is an association between decreased E-Cadherin immunoexpression and tumor recurrence in low-grade and non-muscle invasive transitional cell carcinoma of the bladder.
PURPOSE: To analyze the role of negative versus positive immunoexpression of E-cadherin in recurrence rate of low-grade bladder tumors. MATERIALS AND METHODS: A total of 180 patients with unifocal, superficial, low-grade, papillary transitional cell carcinoma of the bladder were included in this study. The E-cadherin expression was evaluated using E-cadherin antibody. The patients were followed up for 36 months. Thereafter, recurrence rate of the tumor was compared between E-cadherin positive and negative groups. RESULTS: Of 180 low-grade carcinomas, E-cadherin immunoexpression was negative in 101 (56%) and positive in 79 (44%) patients. The recurrence rate in negative and positive groups was 65.6% and 37.9%, respectively. Negative in comparison with positive E-cadherin expression was associated with more disease recurrence (P = .045). CONCLUSION: There is an association between decreased E-Cadherin immunoexpression and tumor recurrence in low-grade and non-muscle invasive transitional cell carcinoma of the bladder.
Authors: Johannes Breyer; Michael Gierth; Sanzhar Shalekenov; Atiqullah Aziz; Julius Schäfer; Maximilian Burger; Stefan Denzinger; Ferdinand Hofstädter; Christian Giedl; Wolfgang Otto Journal: World J Urol Date: 2015-09-22 Impact factor: 4.226
Authors: Maha Hussain; Stephanie Daignault; Neeraj Agarwal; Petros D Grivas; Arlene O Siefker-Radtke; Igor Puzanov; Gary R MacVicar; Ellis Glenn Levine; Sandy Srinivas; Przemyslaw Twardowski; Mario A Eisenberger; David I Quinn; Ulka N Vaishampayan; Evan Y Yu; Scott Dawsey; Kathleen C Day; Mark L Day; Mahmoud Al-Hawary; David C Smith Journal: Cancer Date: 2014-05-06 Impact factor: 6.860
Authors: Amrallah A Mohammed; Hani El-Tanni; Hani M El-Khatib; Ahmad A Mirza; Abdulrahim A Mirza; Turki H Alturaifi Journal: Oncol Rev Date: 2016-12-14
Authors: Alessandro Apollo; Valerio Ortenzi; Cristian Scatena; Katia Zavaglia; Paolo Aretini; Francesca Lessi; Sara Franceschi; Sara Tomei; Carlo Alberto Sepich; Paolo Viacava; Chiara Maria Mazzanti; Antonio Giuseppe Naccarato Journal: PLoS One Date: 2019-01-16 Impact factor: 3.240
Authors: Alexander Schulz; Ielizaveta Gorodetska; Rayk Behrendt; Susanne Fuessel; Kati Erdmann; Sarah Foerster; Kaustubh Datta; Thomas Mayr; Anna Dubrovska; Michael H Muders Journal: Front Oncol Date: 2020-01-21 Impact factor: 6.244
Authors: Sławomir Poletajew; Łukasz Fus; Tomasz Ilczuk; Piotr Wojcieszak; Małgorzata Sękowska; Wojciech Krajewski; Aleksander Wasiutyński; Barbara Górnicka; Piotr Radziszewski Journal: Cent Eur J Immunol Date: 2018-12-31 Impact factor: 2.085